SEC Form 4Coverage since Jun 1, 2026
$RARE insider trading
Over the last 12 months, Ultragenyx Pharmaceutical insiders reported no purchases and 6 sales totaling $527K across SEC Form 4 filings. 83% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $527K 6 events
- Events · 12m
- 6 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 83% pre-arranged plans
Side
Price · $RARE · 12Mvia TradingView
Top insiders · 12m
Horn HowardChief Financial Officer3× · $383K
Parschauer Karah HerdmanEVP and Chief Legal Officer2× · $94K
Sanders Corazon (Corsee) D.—1× · $50K
All insider trades
6 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer · O | ▼ Sale | 1,900 | $24.92 | $47K | -2% | plan |
| Aug 3, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | 4,696 | $24.92 | $117K | -4.6% | plan |
| Jul 1, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | 4,698 | $33.13 | $156K | -4.4% | plan |
| Jun 15, 2026 | Sanders Corazon (Corsee) D.D | ▼ Sale | 2,000 | $25.05 | $50K | -8.7% | — |
| Jun 15, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer · O | ▼ Sale | 1,899 | $24.62 | $47K | -2% | plan |
| Jun 1, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | 4,653 | $23.77 | $111K | -4.2% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RARE feed.